

Astrid A M Van Der Veldt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7394245/publications.pdf>

Version: 2024-02-01

66
papers

1,533
citations

566801

15
h-index

395343

33
g-index

69
all docs

69
docs citations

69
times ranked

2309
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival of stage IV melanoma in Belgium and the Netherlands. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
2	Discontinuation of anti-PD-1 monotherapy in advanced melanoma” Outcomes of daily clinical practice. <i>International Journal of Cancer</i> , 2022, 150, 317-326.	2.3	12
3	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2022, 160, 261-272.	1.3	7
4	The unfavorable effects of COVID-19 on Dutch advanced melanoma care. <i>International Journal of Cancer</i> , 2022, 150, 816-824.	2.3	18
5	Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells. <i>Clinical Cancer Research</i> , 2022, 28, 215-226.	3.2	5
6	Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium. <i>Neuro-Oncology</i> , 2022, 24, 326-328.	0.6	5
7	Brain metastases: the role of clinical imaging. <i>British Journal of Radiology</i> , 2022, 95, 20210944.	1.0	18
8	Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma. <i>Annals of Diagnostic Pathology</i> , 2022, 58, 151909.	0.6	1
9	Genome-wide aneuploidy detected by mFastSeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. <i>Molecular Oncology</i> , 2022, 16, 2086-2097.	2.1	8
10	Anti-PD-1: When to Stop Treatment. <i>Current Oncology Reports</i> , 2022, 24, 905-915.	1.8	5
11	Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. <i>Lancet Oncology</i> , The, 2022, 23, 833-835.	5.1	18
12	Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography. <i>Journal of Personalized Medicine</i> , 2022, 12, 726.	1.1	2
13	Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2022, 187, 381-391.	1.4	14
14	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. <i>Nature Medicine</i> , 2022, 28, 1178-1188.	15.2	121
15	Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9546-9546.	0.8	0
16	Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. <i>Melanoma Research</i> , 2022, 32, 460-468.	0.6	7
17	Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse. <i>Cancers</i> , 2022, 14, 2854.	1.7	9
18	Adjuvant treatment of in-transit melanoma: Addressing the knowledge gap left by clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9577-9577.	0.8	0

#	ARTICLE	IF	CITATIONS
19	The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9605-TPS9605.	0.8	19
20	Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9501-9501.	0.8	12
21	Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 274.e1-274.e16.	0.9	12
22	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. <i>British Journal of Cancer</i> , 2021, 124, 1222-1230.	2.9	16
23	Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. <i>European Journal of Cancer</i> , 2021, 144, 242-251.	1.3	16
24	Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition. <i>Frontiers in Immunology</i> , 2021, 12, 627186.	2.2	6
25	Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. <i>BMC Cancer</i> , 2021, 21, 323.	1.1	22
26	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. <i>Cancers</i> , 2021, 13, 1370.	1.7	9
27	Biomarker-Oriented Therapy in Bladder and Renal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2832.	1.8	18
28	Remarkable Healthy Cohort of Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1092-1093.	0.8	0
29	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135.	2.0	6
30	The BRAF P.V600E Mutation Status of Melanoma Lung Metastases Cannot Be Discriminated on Computed Tomography by LIDC Criteria nor Radiomics Using Machine Learning. <i>Journal of Personalized Medicine</i> , 2021, 11, 257.	1.1	4
31	Efficacy of checkpoint inhibition in advanced acral melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21527-e21527.	0.8	0
32	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2826.	1.7	11
33	False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (Tâ€¦VEC). <i>Journal of Surgical Oncology</i> , 2021, 124, 1161-1165.	0.8	1
34	Assessment of imaging biomarkers in the follow-up of brain metastases after SRS. <i>Neuro-Oncology</i> , 2021, 23, 1983-1984.	0.6	4
35	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. <i>Cancers</i> , 2021, 13, 4639.	1.7	9
36	Primary Melanoma Characteristics of Metastatic Disease: A Nationwide Cancer Registry Study. <i>Cancers</i> , 2021, 13, 4431.	1.7	12

#	ARTICLE	IF	CITATIONS
37	Hospital Variation in Cancer Treatments and Survival Outcomes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. <i>Cancers</i> , 2021, 13, 5077.	1.7	1
38	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. <i>Lancet Oncology</i> , 2021, 22, 1681-1691.	5.1	118
39	Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation. <i>ESMO Open</i> , 2021, 6, 100303.	2.0	7
40	Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. <i>ESMO Open</i> , 2021, 6, 100320.	2.0	10
41	Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. <i>Eur Urol</i> 2019;76:151-6. <i>European Urology</i> , 2020, 77, e76-e77.	0.9	0
42	Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective. <i>European Journal of Cancer</i> , 2020, 136, 132-139.	1.3	120
43	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020, 141, 171-184.	1.3	65
44	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. <i>Cancers</i> , 2020, 12, 2072.	1.7	16
45	Surgery for Unresectable Stage IIIc and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	1.7	11
46	Nivolumab plus ipilimumab as neoadjuvant treatment in primary advanced renal cell tumors: Cutting edges for cutting-edge surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 553-554.	0.8	1
47	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2020, 8, e000586.		39
48	Real-world outcomes of advanced melanoma patients not represented in phase III trials. <i>International Journal of Cancer</i> , 2020, 147, 3461-3470.	2.3	27
49	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. <i>Thyroid</i> , 2020, 30, 966-973.	2.4	57
50	⁶⁸ Ga-PSMA-Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1607-1614.	2.8	11
51	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020, 12, 1003.	1.7	15
52	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD-1 Treated Patients in the Dutch Melanoma Treatment Registry. <i>Clinical Cancer Research</i> , 2020, 26, 2268-2274.	3.2	112
53	First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 10002-10002.	0.8	57
54	Early response marker during pembrolizumab treatment in metastatic urothelial cancer: Temporal shift in peripheral CD4 T cells expressing chemokine receptors. <i>Journal of Clinical Oncology</i> , 2020, 38, 5033-5033.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy.. Journal of Clinical Oncology, 2020, 38, 10032-10032.	0.8	0
56	Author's reply to: The real-world outcome of metastatic melanoma: Unknown primary <i>vs</i>. known cutaneous. International Journal of Cancer, 2019, 145, 3175-3176.	2.3	1
57	Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. , 2019, 7, 182.		29
58	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
59	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	0.8	83
60	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1931-1939.	3.3	53
61	CD45RA+CCR7 ⁺ CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab. , 2019, 7, 149.		44
62	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. Journal of Clinical Oncology, 2019, 37, TPS9605-TPS9605.	0.8	16
63	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. British Journal of Cancer, 2018, 118, 1296-1301.	2.9	49
64	Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients.. Journal of Clinical Oncology, 2018, 36, e21239-e21239.	0.8	0
65	Correlation between nivolumab exposure and treatment outcome in NSCLC.. Journal of Clinical Oncology, 2018, 36, 9057-9057.	0.8	1
66	Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. European Urology, 2017, 72, 411-423.	0.9	89